Impact of Diabetes Mellitus and blood glucose levels on the results of treatment of patients with ST-elevation myocardial infarction undergoing percutaneous coronary interventions

The aim of this study was to evaluate the impact of diabetes mellitus (DM) and glucose levels on the results of treatment of patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary interventions (PCIs). Materials and methods. Data were collected from all patients (n=1280) with STEMI who were admitted to the coronary care unit and underwent PCIs from 2006 to 2015. 212 (16.6%) patients with DM were compared with 1068 (83.4%) patients without DM (non-DM group). To investigate the influence of the blood glucose levels, all patients were divided into two groups above and below the median of blood glycemia (7.52 mmol/l). Results. Thus, 634 patients with high level of blood glycemia (>7.52 mmol/l) were compared with 635 patients with low level of blood glycemia (≤7.52 mmol/l). In comparing of DM and non-DM groups there were no differences in the rate of death (5.2% vs 4.2%, р=0.526), stent thrombosis (1.4% vs 1.0%, р=0.622), recurrent myocardial infarction (MI) (1.4% vs 1.2%, р=0.813) and major adverse cardiac events (MACE) (7.5% vs 5.4%, р=0.228), which included in-hospital death, recurrent MI and stent thrombosis. The rates of angiographic success (92.9% vs 93.8%, р=0.625) and no-reflow (6.6% vs 5%, р=0.327) also were comparable between groups. The rates of death (6.3% vs 2.5%, р=0.001), MACEs (7.6% vs 4.1%, р=0.008), and no-reflow (6.9% vs 3.6%, р=0,009) were significantly higher in patients with high level of blood glycemia (>7.52 mmol/l). Angiographic success rate (95.1% vs 92.1%, р=0.029) was higher in patients with low level of glycemia (≤7.52 mmol/l). After multivariate adjustment, high level of blood glycemia (>7.52 mmol/l) remained an independent predictor of death (OR=2.28; 95% CI 1.18-4.40, р=0.014), MACE (OR=2.08; 95% CI 1.16-3.75, р=0.014) and no-reflow (OR=2.07; 95% CI 1.15-3.74, р=0.015). At the same time DM wasn’t associated with death, MACE or no-reflow. Conclusion. High level of blood glycemia was an independent predictor of death, MACE and no-reflow in patients with STEMI, undergoing PCI. The presence of DM was not associated with worse in-hospital outcomes.

1. Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. European Heart Journal Supplements. 2012;14(suppl B):B4–13. DOI: 10.1093/eurheartj/sus002

2. Kakorin S. V., Karamyshev D. V., Mkrtumyan А. M., Nefedova G. А. Clinico-morphological features of acute myocardial infarctionin patients with type 2 diabetes mellitus. Russian Heart Journal. 2014;13(6):347–53. [Russian: Какорин С. В., Карамышев Д. В., Мкртумян А. М., Нефедова Г. А. Клинико-морфологические особенности острого инфаркта миокарда у больных сахарным диабетом 2 типа. Сердце: журнал для практикующих врачей. 2014;13(6):347-53]

3. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541–619. DOI: 10.1093/eurheartj/ehu278

4. Kuznetsov V. A., Yaroslavskaya E. I., Pushkarev G. S., Zyryanov I. P., Bessonov I. S., Gorbatenko E. A. et al. Interrelation of transcutaneous coronary interventions for acute forms of coronary heart disease and mortality parameters in tyumen region inhabitants. Russian Journal of Cardiology. 2014;19(6):42–6. [Russian: Кузнецов В. А., Ярославская Е. И., Пушкарев Г. С., Зырянов И. П., Бессонов И. С., Горбатенко Е. А. и др. Взаимосвязь чрескожных коронарных вмешательств при острых формах ишемической болезни сердца и показателей смертности населения Тюменской области. Российский кардиологический журнал. 2014;19(6):42–6]. DOI: 10.15829/1560-4071-2014-6-42-46

5. Аlekyan B. G., Grigor’yan А. M., Staferov А. V. X-ray endovascular diagnostics and treatment of heart and vascular diseases in the Russian Federation - 2016 year. – M.: LA Graphics; 220 p. [Russian: Алекян Б. Г., Григорьян А. М., Стаферов А. В. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации – 2016 год. – М.: ЛА Графикс; 2017. -220с.]. ISBN 978-5-4465-1503-5

6. Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Xu K et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. International Journal of Cardiology. 2013;167(6):2572–9. DOI: 10.1016/j. ijcard.2012.06.054

7. Zhang J-W, Zhou Y-J, Cao S-J, Yang Q, Yang S-W, Nie B. Impact of stress hyperglycemia on in-hospital stent thrombosis and prognosis in nondiabetic patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention: Coronary Artery Disease. 2013;24(5):352–6. DOI: 10.1097/ MCA.0b013e328361a942

8. Koracevic GP. Proposal of a New Approach to Study and Categorize Stress Hyperglycemia in Acute Myocardial Infarction. The Journal of Emergency Medicine. 2016;51(1):31–6. DOI: 10.1016/j. jemermed.2015.03.047

9. Dedov I. I., Shestakova M. V., Aleksandrov A. A., Galstyan G. R., Grigoryan O. R., Esayan R. M. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (6th edition). Diabetes. 2013;1S:1–121. [Russian: Дедов И. И., Шестакова М. В., Александров А. А., Галстян Г. Р., Григорян О. Р., Есаян Р. М. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М. В. Шестаковой (6-й выпуск). Сахарный диабет. 2013;1S:1-121]

10. Rudnov V. A. Clinical Significance and Possible Ways of Hyperglycemia Correction in Critical Conditions. Emergency medicine. 2013;2(49):54–61. [Russian: Руднов В. А. Клиническая значимость и возможные пути коррекции гипергликемии при критических состояниях. Медицина неотложных состояний. 2013;2(49):54-61]

11. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP et al. Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans. Diabetes. 2006;55(6):1807–12. DOI: 10.2337/db05-1543

12. Bessonov IS, Kuznetsov VA, Potolinskaya YV, Zyrianov IP, Sapozhnikov SS. Impact of hyperglycemia on the results of percutaneous coronary interventions in patients with acute ST-segment elevation myocardial infarction. Therapeutic Archive. 2017;89(9):25–9. [Russian: Бессонов И. С., Кузнецов В. А., Потолинская Ю. В., Зырянов И. П., Сапожников С. С. Влияние гипергликемии на результаты чрескожных коронарных вмешательств у больных острым инфарктом миокарда с подъемом сегмента ST. Терапевтический архив. 2017;89(9):25-9]. DOI: 10.17116/terarkh201789925-29

13. Naber CK, Mehta RH, Jünger C, Zeymer U, Wienbergen H, Sabin GV et al. Impact of Admission Blood Glucose on Outcomes of Nondiabetic Patients With Acute ST-Elevation Myocardial Infarction (from the German Acute Coronary Syndromes [ACOS] Registry). The American Journal of Cardiology. 2009;103(5):583–7. DOI: 10.1016/j.amjcard.2008.11.005

14. Jensen CJ, Eberle HC, Nassenstein K, Schlosser T, Farazandeh M, Naber CK et al. Impact of hyperglycemia at admission in patients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI. Clinical Research in Cardiology. 2011;100(8):649–59. DOI: 10.1007/s00392-011-0290-7

15. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA et al. 5-Year Prognostic Value of No-Reflow Phenomenon Aſter Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. Journal of the American College of Cardiology. 2010;55(21):2383–9. DOI: 10.1016/j.jacc.2009.12.054

16. Tisminetzky M, Joffe S, McManus DD, Darling C, Gore JM, Yarzebski J et al. Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction. Diabetes and Vascular Disease Research. 2014;11(3):182–9. DOI: 10.1177/1479164114524235

17. Gore MO, Patel MJ, Kosiborod M, Parsons LS, Khera A, de Lemos JA et al. Diabetes Mellitus and Trends in Hospital Survival Aſter Myocardial Infarction, 1994 to 2006: Data from the National Registry of Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes. 2012;5(6):791–7. DOI: 10.1161/CIRCOUTCOMES.112.965491

18. Gruppetta M, Calleja N, Fava S. Long-Term Survival Aſter Acute Myocardial Infarction and Relation to Type 2 Diabetes and Other Risk Factors. Clinical Cardiology. 2010;33(7):424–9. DOI: 10.1002/clc.20776

19. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T et al. Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610–9. DOI: 10.1161/ CIRCULATIONAHA.107.188629

20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393